Merck acquires Cidara Therapeutics

Merck has initiated the process to acquire Cidara Therapeutics, reinforcing its position in the biotechnology sector, particularly in respiratory diseases. The company has completed a cash tender offer, agreeing to buy Cidara shares at $221.50 each. Approximately 27.1 million shares, representing about 85.96% of Cidara's outstanding stock, were tendered and accepted. The acquisition will be finalized with a merger that converts the remaining shares into the same cash consideration, making Cidara a wholly owned subsidiary of Merck. Subsequently, Cidara's shares will be delisted from Nasdaq.

The transaction, valued at $9.2 billion, will be classified as an asset acquisition for Merck. This strategic move is set to increase Merck's research and development expenses by approximately $9.0 billion in 2026, with an anticipated reduction in earnings per share by about $0.30 during the first year post-acquisition. Robert M. Davis, Merck’s CEO, emphasized that the acquisition aligns with the company's business development strategy by blending compelling science with value, particularly enhancing its respiratory portfolio.

Cidara's CD388, an investigational antiviral currently in Phase 3 trials, is central to the acquisition. Designed as a long-acting agent, CD388 aims to prevent symptomatic influenza in high-risk populations, offering season-long protection. Preliminary data suggest its efficacy against influenza A and B strains, positioning it as a significant addition to Merck's respiratory disease offerings.

This acquisition is part of a broader strategic push by Merck to expand its footprint in respiratory pharmaceuticals, coming on the heels of its recent acquisition of Verona Pharma. As Merck continues to extend its portfolio, this deal further intensifies competition in the biotech sector, where established firms and emerging startups are aggressively investing in innovation to secure market leadership.

Looking forward, Merck will need to navigate regulatory clearance to fully integrate Cidara into its operations. Once regulatory approvals are secured, the focus will shift to how quickly Merck can bring CD388 to market, which will be key in realizing synergies from this acquisition.